buyout·deskPrivate equity, daily
Wed, Sep 23, 2026
Latest issueWednesday, September 23, 2026
16 deals · Updated Wed, Sep 23, 2026 at 3:28 PM PDT·Full deal sheet
Add-on·Healthcare/Pharma Services·September 23, 2026

AVS Bio closes Biorbyt acquisition

The Cambridge-based supplier adds more than one million research products and an ecommerce platform.

More healthcare deals →

BuyerAVS Bio
TargetBiorbyt
SponsorArlington Capital Partners
TypeAdd-on
IndustryHealthcare
Sub-sectorPharma Services

Arlington Capital Partners-backed AVS Bio acquired Biorbyt, a Cambridge, UK-based supplier of life science research reagents. Founded in 2011, Biorbyt offers more than one million products, including antibodies, proteins, ELISA kits, small molecules and molecular biology reagents.

Its customers include pharmaceutical companies, biotechnology businesses and academic researchers. Biorbyt will continue under its existing leadership within AVS Bio.

Based in Norwich, Connecticut, AVS Bio supplies biological materials and services used in the development and manufacture of vaccines, therapeutics and biologics.